Impact of connecting tuberculosis directly observed therapy short-course with smoking cessation on health-related quality of life
![Thumbnail](/bitstream/handle/10576/37310/pdf-66083-5582.pdf.jpg?sequence=3&isAllowed=y)
View/ Open
Publisher version (Check access options)
Check access options
Date
2012Author
Awaisu, AhmedHaniki Nik Mohamed, Mohamad
Noordin, Noorliza Mohamad
Muttalif, Abdul Razak
Aziz, Noorizan Abd
Syed Sulaiman, Syed Azhar
Mahayiddin, Aziah Ahmad
...show more authors ...show less authors
Metadata
Show full item recordAbstract
Background: With evolving evidence of association between tuberculosis (TB) and tobacco smoking, recommendations for the inclusion of tobacco cessation interventions in TB care are becoming increasingly important and more widely disseminated. Connecting TB and tobacco cessation interventions has been strongly advocated as this may yield better outcomes. However, no study has documented the impact of such connection on health-related quality of life (HRQoL). The objective of this study was to document the impact of an integrated TB directly observed therapy short-course (DOTS) plus smoking cessation intervention (SCI) on HRQoL. Methods. This was a multi-centered non-randomized controlled study involving 120 TB patients who were current smokers at the time of TB diagnosis in Malaysia. Patients were assigned to either of two groups: the usual TB-DOTS plus SCI (SCIDOTS group) or the usual TB-DOTS only (DOTS group). The effect of the novel strategy on HRQoL was measured using EQ-5D questionnaire. Two-way repeated measure ANOVA was used to examine the effects. Results: When compared, participants who received the integrated intervention had a better HRQoL than those who received the usual TB care. The SCIDOTS group had a significantly greater increase in EQ-5D utility score than the DOTS group during 6 months follow-up (mean SD = 0.98 0.08 vs. 0.91 0.14, p = 0.006). Similarly, the mean scores for EQ-VAS showed a consistently similar trend as the EQ-5D indices, with the scores increasing over the course of TB treatment. Furthermore, for the EQ-VAS, there were significant main effects for group [F (1, 84) = 4.91, p = 0.029, 2 = 0.06], time [F (2, 168) = 139.50, p = < 0.001, 2 = 0.62] and group x time interaction [F (2, 168) = 13.89, p = < 0.001, 2 = 0.14]. Conclusions: This study supports the evidence that an integrated TB-tobacco treatment strategy could potentially improve overall quality of life outcomes among TB patients who are smokers. 2012Awaisu et al; licensee BioMed Central Ltd.
Collections
- Pharmacy Research [1243 items ]